BTIG Maintains Buy on Guardant Health, Raises Price Target to $210
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsPrice Target
BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $195 to $210.
BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $195 to $210.